Work

Abstract CT109: A phase 0/1 study of PRMT5 inhibitor BMS-986504 in recurrent glioblastoma participants with MTAP deletion

Year: 2026

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2026-ct109

Authors: Nader Sanai, Shwetal Mehta, Artak Tovmasyan, Jocelyn Harmon, Hualin Zhang, Amy Hong, Nadia Gonzalez, Tearra Sheidler, Brian Pham, Yoshie Umemura, William Knight, Tigran Margaryan, An-Chi Tien

Institution: Barrow Neurological Institute

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7154724680

Cites:

Cited by:

Related to: